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Introduction: Hyperechogenicity of the substantia nigra (SN+) is a risk marker for
Parkinson’s disease (PD) which can be detected before the diagnosis. In healthy
individuals, SN+ has been associated with slight deficits in specific cognitive functions,
suggesting cognitive impairment as a possible pre-diagnostic marker for PD. However,
the pattern of cognitive deficits associated with SN+ has not yet been compared with
those present in PD.
Methods: Data of 262 healthy individuals with normal echogenicity (SN−) and 48
healthy individuals with SN+ were compared with 82 early stage PD patients using
the “Consortium to Establish a Registry for Alzheimer’s disease” test battery. First, the
test clusters (factors) were identified using a principal component analysis (PCA). Mean
group performance of cognitive tests belonging to distinct factors, according to the PCA,
and single subtest performances were compared using analyses of variance. Second,
the number of individuals with abnormal cognitive performances (z-score < −1.0) were
compared between groups.
Results: Verbal memory, semantic and executive function, and praxis were identified
as components of cognitive performances. The SN+ group performed significantly
worse than the SN− group in tests assessing semantic and executive function, with
a non-significant decrease in verbal memory. On the subtest level, individuals of the
SN+ group scored significantly lower than the SN− group on the Boston Naming Test
(BNT; p = 0.008). In all subtests, the percentages of PD patients with values below the
cut-off for abnormal performance were higher than in the SN− group. Moreover, more
individuals from the SN+ group scored below the cut-off in the BNT (SN− = 8.4%,
SN+ = 20.8%, p = 0.01) and TMT-B (SN− = 6.9%, SN+ = 16.7%, p = 0.02),
compared to the SN− group.
Conclusion: This study confirms poorer performance of healthy individuals with SN+
compared to SN− in specific cognitive domains. However, against the SN− group, the
cognitive profile of the SN+ group was not fully consistent with the profile of early PD
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patients. Our data argues that cognitive impairment associated with SN+ might differ
slightly from that seen in early PD. Compensational mechanisms in the early phases
of neurodegeneration, and the fact that only a subgroup of SN+ will develop PD, may
partly explain these differences.
Keywords: substantia nigra hyperechogenicity, Parkinson’s disease, cognition, transcranial sonography,
prodromal Parkinson’s disease
INTRODUCTION
Idiopathic Parkinson’s disease (PD) is clinically diagnosed
according to the presence of the cardinal motor symptoms.
However, in accordance with the pathological degenerative
process that starts many years before clinical diagnosis can be
made, several non-motor and unspecific early motor symptoms
may be observed. This very early neurodegenerative phase is
termed prodromal, or pre-diagnostic, PD (Berg et al., 2015).
Well known prodromal non-motor symptoms are hyposmia,
REM sleep behaviour disorder (RBD), depression and autonomic
dysfunction (Berg et al., 2015), but the role of slight impairment
in cognition in the prodromal phase is not yet entirely clear. In
the clinical course of PD, cognitive deficits have been shown not
only to be a marker of late stages, but may also occur in earlier
phases of the disease (Foltynie et al., 2004; Muslimovic et al.,
2005; Broeders et al., 2013a). Interestingly, first studies on this
matter indicate that cognitive dysfuction may even occur in the
prodromal stage (Postuma et al., 2012; Pont-Sunyer et al., 2015;
Schrag et al., 2015; Chahine et al., 2016).
Increased echogenicity of the substantia nigra (SN+),
visualized by transcranial sonography (TCS) has been
demonstrated to increase the risk for future PD diagnosis
(Berg et al., 2013a). This ultrasound marker can be identified
by experienced sonographers in individuals with a sufficient
temporal bone window. At the group level, SN+ in still healthy
individuals has previously been shown to be associated with slight
impairments in cognition (Liepelt et al., 2008; Hoeppner et al.,
2009). As SN+ increases the risk for PD (more than 20-fold in
individuals older than 50 years of age, when followed for 5 years)
(Berg et al., 2013a), it seems plausible that cognitive deficits in
individuals with SN+ may present a specific pattern typical for
premotor PD. Moreover, a continuum in the type and degree
of cognitive decline in the different stages of PD (prodromal –
early – mid – late) seems likely. But, this assumption has never
been tested. We therefore decided to take the first part of these
stages and compared the cognitive performance between groups
of low (SN−) and high (SN+) echogenicity (with the latter
ones supposedly at higher risk for PD) and a group of early
PD patients, in order to identify a specific pattern of cognitive
deficits in elderly with increased risk of future PD.
MATERIALS AND METHODS
The study was approved by the ethical committee of the Medical
Faculty of the University of Tübingen, Germany. All procedures
were in accordance with the Declaration of Helsinki, and
informed consent was obtained from all participants.
Participants
Data of 427 healthy elderly individuals from the “Prospective
evaluation of Risk factors for Idiopathic Parkinson’s Syndrome”
(PRIPS) study (Berg et al., 2013b), who were later included
and followed in the “Tübinger Evaluation of Risk Factors for
Early Detection of Neurodegeneration” (TREND) study1, were
analyzed. This cohort was chosen, as these individuals were
recruited without screening for any prodromal markers, so as
to avoid the overrepresentation of prodromal PD (individuals
primarily from large companies who were older than 50 years of
age were asked to participate) (Berg et al., 2013b).
Through the outpatient clinic of the Department of
Neurology, University of Tübingen, 172 elderly (older than
50) patients with PD were recruited. Patients with PD were
diagnosed according to the United Kingdom Brain Bank
Criteria. All patients were receiving optimal medication for their
symptoms. Only patients with a Hoehn and Yahr Score of ≤2.5
were included into the present analysis, in order to characterize
the group of PD as early stage. Other exclusion criteria for all
participants were as follows: Moderate or severe depression
defined by a score of or above 18 in the “Beck Depression
Inventory,” manifest dementia defined by a score in Mini-Mental
Status Examination (MMSE) ≤24, mother tongue other than
German, history of stroke, brain tumor or medication that could
interfere with test performance. For healthy individuals a score
of>5 in the motor part of the Unified Parkinson’s Disease Rating
Scale (UPDRS) was interpreted as indicative of parkinsonism.
Those persons were also excluded from data analysis (see
Figure 1).
Transcranial Sonography
The status (SN−, SN+) of the healthy participants was defined
by measuring the area of increased echogenicity at the anatomical
site of the substantia nigra in the hypoechogenic brainstem using
TCS. A hyperechogenic area larger than 0.22 cm2 on either
side, which corresponded to the 90th percentile of the TREND
cohort, was considered as SN+. For details of the examination of
substantia nigra using TCS and specific cut-off values, see (Berg
et al., 2006; Walter and Skoloudik, 2014).
Cognitive Assessment and Scores
The following subtests of the German version of the “Consortium
to Establish a Registry for Alzheimer’s disease” (CERAD) plus
battery were administered (Morris et al., 1988): Verbal Fluency
(semantic fluency), Verbal Memory Test (word list learning,
delayed recall, and recognition), modified Boston Naming Test
1http://www.trend-studie.de
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(BNT), Visuo-constructional Praxis (Total figure drawing and
delayed figure recall), and the Trail Making Test (TMT) parts A
and B.
Raw scores of the tests were converted to age, sex, and
education-corrected z-scores, as provided in the CERAD
manual (Aebi, 2002). For the comparison of abnormal
cognitive performances (explained below), a z-score below
−1.0, representing a score lower than one standard deviation
(SD) from the mean performance of the normal population,
was defined as low performance in each subtest. In general, the
cut-off for the definition of low performance can be defined
by considering the nature of the analyzed cohort or desired
sensitivity/specificity. For instance, mild cognitive impairment
(MCI) in PD has been defined as a domain score lower than
z = −1.5 (Aarsland et al., 2010). In this study, we chose a
more liberal cut-off value to identify slight deficits in cognitive
performance that could be expected in healthy individuals who
do not yet have MCI, but who may be in the early stages of an
ongoing neurodegenerative process (Lezak, 2012).
Statistical Analyses
Analyses of cognitive performances were performed in an
explorative manner for the purpose of identifying a common
pattern between the risk and PD groups. Statistical analyses
of neuropsychological data were performed in two approaches.
First, performance of the CERAD subtests was compared
between groups; second, comparisons of the percentage of
individuals who scored below the defined cut-off (z < −1.0)
were conducted. Group differences in demographical variables
(sex, age, and education) were analyzed using a χ2 or
a one-way analysis of variance (ANOVA). As part of the
first approach, a principal component analysis (PCA, oblique
rotation) was performed to define the clusters (factors) of
the CERAD subtests, interpreted as cognitive domains. After
defining the factors according to the PCA, mean z-values
of those CERAD subtests with the highest loading on one
factor were calculated and compared between study groups by
using an ANOVA. Between-group performances in each single
CERAD subtest (dependent variables) were also analyzed by
an ANOVA with group membership (SN−, SN+, and PD) as
the independent factor and, when significant, were followed
by subsequent post hoc tests of Bonferroni or Games-Howell
as appropriate. Correlations between the cognitive tests and
the total (right + left) area echogenicity in non-PD groups
were also performed using the Pearson’s correlation. In the
second approach, χ2 tests were performed within groups after
re-coding the CERAD test results (continuous variable) into
dichotomous categorical variables as higher or lower than the
cut-off score (z = −1.0, abnormal performance). SPSS Statistics
22.0.0 (SPSS Ltd., Chicago, IL, USA) was used for statistical
analyses.
RESULTS
Characteristics of Study Groups
An overview of participants excluded from data analysis is given
in Figure 1. In total, data of 392 participants was analyzed (see
Table 1 for details of demographics). Of those, individuals with
SN+ (n = 48) and PD (n = 82) were significantly older than
persons with SN− (n = 262, p < 0.001). Members of both
SN groups had a higher level of education than PD patients
(p = 0.002). Percentage of males did not differ statistically
between study groups.
FIGURE 1 | Flowchart of the study population showing the exclusion criteria.
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Principal Component Analysis
The PCA was conducted on nine neuropsychological tests (see
Table 2) with oblique (related) rotation (oblimin). The Kaiser–
Meyer–Olkin (KMO) measure verified the sampling adequacy
for the analysis (KMO = 0.71). Bartlett’s test of sphericity
(χ2(36)= 797.69, p< 0.001) indicated that correlations between
items were sufficiently large for PCA. Three components had
eigenvalues over Kaiser’s criterion of 1 and, in combination,
explained 60.5% of the variance. Table 2 shows the factor loadings
after rotation. According to the items that gather on the same
factors, factor 1 was assigned as verbal memory (31.6% of
variance explained), factor 2 as semantic and executive function
(15.6% of variance explained) and factor 3 as praxis (13.3% of
variance explained).
Domain and Subtest Performances of
SN−, SN+, and PD Groups
First, the mean z-scores calculated for each factor were compared
between groups (Table 3). PD patients had significantly lower
mean z-scores in verbal memory (factor 1) and praxis tests
(factor 3) than SN−, but not in tests assessing semantic and
executive function (factor 2). In contrast, individuals with SN+
showed significantly lower mean z-scores in tests associated with
semantic and executive function (factor 2) than participants with
SN− [Welch F(2,107) = 4.8, p = 0.01, Games-Howell p = 0.02],
but not in the mean z-scores of tests related to verbal memory
(factor 1) and praxis (factor 3). Interestingly, mean factor z-scores
TABLE 1 | Demographical characteristics of the groups.
SN− SN+ PD P-value
N 262 48 82
Age (mean ± SD) 63.6 (5.5) 66.3 (5.9) 67.0 (6.5) <0.001a∗
Male, n (%) 171 (65) 37 (77) 54 (66) 0.27+
Education, years 14.1 14.0 12.8 0.002a∗
N, number; SD, standard deviation; SN, substantia nigra. ∗P-value significant.
aOne-way ANOVA. +χ2 test.
TABLE 2 | Loadings of the principal component analysis showing a
three-factor model for cognitive domains.
Neuropsychological
test
Component 1
verbal
memory
Component 2
semantic and
executive function
Component 3
praxis
Boston naming test 0.55
Semantic fluency 0.53
Word list learning 0.82
Word list delayed recall 0.87
Word list recognition 0.72
Figure drawing 0.86
Delayed figure recall 0.85
Trail making test-A 0.81
Trail making test-B 0.80
Explained variance 31.6% 15.6% 13.3%
between patients with PD and individuals with SN+ only differed
significantly in praxis function (factor 3).
Comparisons between PD and SN− groups on the subtest
level yielded significant results in all but word list learning
and TMT tests. The SN+ group performed significantly worse
than the SN− group only in the BNT [Welch F(2,100) = 8.4,
p< 0.001, Games-Howell p= 0.008]. Contrary to the SN− group,
members of the SN+ group performed similar to the PD group
on the word list delayed recall test (SN+ mean = −0.27, PD
mean=−0.29), although this was not significantly different from
the performance of the SN− group. Additionally, no significant
correlation was detected between tests results and the total area
of echogenicity (Supplementary Table).
Frequency of Individuals with Values
below Cut-Off
Chi-square tests showed that the percentages of PD patients
with a performance below cut-off were significantly higher
compared to individuals with SN− in all tests (Table 4). In
contrast, PD and SN+ deviated significantly only in the delayed
figure recall test (p = 0.002). The SN+ group had a higher
frequency of individuals with abnormal performance in the
BNT (SN− = 8.4%, SN+ = 20.8%, p = 0.01), and TMT-B
(SN− = 6.9%, SN+ = 16.7%, p = 0.02) compared to the SN−
group. Similar to the mean value comparison, the percentage of
individuals who scored below the cut-off in the word list delayed
recall test in the SN+ group (20.8%) was close to the PD group
(23.2%), although it lacked significance compared to the SN−
group (13.4%; p= 0.18) (Figure 2).
DISCUSSION
In this cross-sectional study, the cognitive performance of healthy
individuals with SN+, a risk factor for the later development of
PD, and of those without this risk factor (SN−) were compared to
patients with early PD using two different statistical approaches.
Our results indicate that the percentage of individuals with
abnormal test performance (<1 SD below norm mean) was
higher in patients with PD compared to the SN− group in
all tests. Furthermore, considering that SN+ is associated with
the prodromal neurodegenerative process leading to PD, our
data support previous findings indicating that cognitive deficits
are observed even in the early stages of PD. Performance of
individuals with SN+ differed from that of SN−, especially
in tests assessing confrontation naming and executive function
and – although not significant – in the verbal memory domain.
Moreover, the SN+ and PD groups did not differ statistically
in memory and language function, and scored similarly in some
tests, with the exception of the visual construction domain.
The three clusters of neuropsychological subtest performances
that were revealed by the PCA analysis are in accordance with
the previously known cognitive domains. Comparing the mean
z-scores of these clusters, the SN+ group showed intermediate
performance, i.e., between SN− and PD groups, in the verbal
memory domain (Table 3). Factor 2 (semantic and executive
function) score was significantly lower in the SN+ compared
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to the SN− group. Likewise, mean performance of the SN+
group in the BNT also was significantly worse than that of
the SN− group. Given that the SN+ group is comprised of
individuals some of which may develop PD in the future, slight
impairments may have already affected their executive functions
and confrontation naming. Previous studies have shown that
performance in these domains can be impaired in early PD
patients (Poletti et al., 2012; Broeders et al., 2013b; Hanna-Pladdy
et al., 2013). Interestingly, although not significant, mean Factor
2, BNT and TMT-B scores were slightly lower in the SN+ group
than in the PD group. This suggests that on a group level,
individuals with SN+ are slightly more impaired than early PD
patients in confrontation naming and executive function. This
inconsistency could be explained either by additional factors,
such as possible compensation due to the dopaminergic therapy
in some patients in the PD group (Kehagia et al., 2010), or by
the possibility that the SN+ group is not an ideal representation
of premotor PD in all cognitive domains. However, when
comparing only the abnormal scores, the PD group had the
highest prevalence in all tests (Table 4).
Studies on cognitive performance in individuals with SN+
are rare, and, due to the fact that only a minority of the
persons involved will develop PD, not as consistent as those
in the early PD group. Along with previous studies reporting
executive dysfunction in the SN+ group (Liepelt et al., 2008;
Hoeppner et al., 2009), our group has in a large cohort recently
shown that SN+ can be associated with a slight decline in
the word list delayed recall test (Yilmaz et al., 2016) which is
in accordance with other reports of memory impairment in
early PD (Aarsland et al., 2009; Broeders et al., 2013b; Schrag
et al., 2015). With a smaller sample size, the present study did
not replicate this finding, but still suggests the tendency of a
decreasing performance in the SN+ group, toward the level of
PD group performance, both in mean score and low performance
comparisons. The lack of a significant correlation between
cognitive scores and the echogenic area was not surprising,
since the echogenicity of substantia nigra do not to change
during the course of the disease (Berg et al., 2005) and only
constitutes a risk marker rather than reflecting the disease
severity.
TABLE 3 | Comparison the groups in CERAD subtest and factor levels.
Neuropsychological test SN−
(mean± SD)
SN+
(mean± SD)
PD
(mean± SD)
P-value
PD vs SN−
P-value
PD vs SN+
P-value
SN+ vs SN−
Factor 1 (verbal memory)g −0.04 (0.7) −0.15 (0.7) −0.33 (0.9) 0.02 ns ns
Word list learningb −0.3 (0.9) −0.3 (1.0) −0.49 (1.1) ns ns ns
Word list delayed recallb −0.03 (0.9) −0.27 (0.8) −0.29 (1.1) 0.02 ns ns
Word list recognitiong 0.22 (0.8) 0.12 (0.9) −0.22 (1.1) 0.004 ns ns
Factor 2 (semantic and executive function)g 0.29 (0.7) 0.03 (0.6) 0.10 (0.9) ns ns 0.02
Boston naming testg 0.34 (0.8) −0.08 (0.9) −0.05 (1.1) 0.008 ns 0.008
Semantic fluencyb 0.06 (1.1) −0.15 (0.8) −0.36 (1.1) 0.005 ns ns
Trail making test-Ag 0.31 (1.1) 0.18 (1.0) 0.07 (1.4) ns ns ns
Trail making test-Bg 0.46 (1.0) 0.18 (0.9) 0.46 (1.5) ns ns ns
Factor 3 (praxis)g 0.28 (0.9) 0.40 (0.9) −0.30 (1) <0.001 <0.001 ns
Figure drawingg 0.25 (0.9) 0.33 (0.8) −0.13 (1.1) 0.02 0.02 ns
Delayed figure recallg 0.31 (1.1) 0.46 (1.1) −0.47 (1.4) <0.001 <0.001 ns
ns, non-significant; b, Post hoc Bonferroni; g, Post hoc Games-Howell.
TABLE 4 | Percentages of individuals per group with a z-score < −1 in the subtests of the CERAD battery.
Groups SN− (%) SN+ (%) PD (%) P-value PD vs SN− P-value PD vs SN+ P-value SN+ vs SN−
Factor 1 (verbal memory)
Word list learning 23.3 25.0 36.6 0.017 ns ns
Word list delayed recall 13.4 20.8 23.2 0.033 ns ns
Word list recognition 12.6 12.5 26.8 0.002 ns ns
Factor 2 (semantic and executive function)
Boston naming test 8.4 20.8 23.2 <0.001 ns 0.01
Semantic fluency 16.4 14.6 28.0 0.02 ns ns
Trail making test-A 11.5 10.4 23.2 0.008 ns ns
Trail making test-B 6.9 16.7 17.9 0.003 ns 0.02
Factor 3 (praxis)
Figure drawing 14.5 10.4 24.4 0.037 ns ns
Delayed figure recall 16.8 14.6 40.2 <0.001 0.002 ns
ns, non-significant.
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FIGURE 2 | Percentages of individuals per group with a z-score < −1. Note the increase in the percentage of word list delayed recall test in the SN+ group,
together with the Boston Naming Test and TMT-B. TMT, Trail Making Test.
Previous studies on cognition in PD risk-groups report
decline in several areas. One study found deficits in the MMSE,
TMT-A, and constructional praxis in patients with REM sleep
behavioral disorder (Youn et al., 2015), whereas another reported
impairment in TMT-B in incidental Lewy body disease (Adler
et al., 2010). Visual short-term memory task and executive
function deficits were also found in healthy individuals with GBA
and LRRK mutations (Thaler et al., 2012; Zokaei et al., 2014).
Executive dysfunctions have also been shown to be present in
the first-degree relatives of PD patients (Dujardin et al., 1999).
One recent study reported executive dysfunction in healthy
adults with hyposmia and reduced dopamine transporter binding
(Chahine et al., 2016). These findings represent a growing body
of evidence that suggest a problem in executive functions in PD
risk-groups, occuring before the clinical diagnosis of PD. A slight
deficit in executive functions was also found to be predictive of
PD in a large prospective population-based study (Ross et al.,
2012). Some of these studies compared the risk group with
healthy controls but did not include PD patients in the analyses.
In our study, however, we included a PD group in order to
validate the finding in the risk group, and to compare the pattern
and degree of cognitive impairment.
The evaluation of cognitive functions in the PD risk-group
may be useful (Adler, 2011), but there are several factors that
complicate the search for the cognitive profile of pre-diagnostic
PD. First of all, PD itself has a heterogeneous cognitive profile
(Svenningsson et al., 2012). Secondly, the rate of progression of
the premotor markers in the pre-diagnostic phase is unknown
(Postuma et al., 2012). Additionally, during the long course
between the beginning of neurodegeneration and clinical PD
diagnosis, (motor or non-motor) symptoms of PD may occur
at different temporal stages (Schrag et al., 2015). Therefore,
detecting or following cognitive decline in PD risk-groups is not
an easy task. Furthermore, all currently known risk or prodromal
factors, with the exception of RBD, are frequently observed in
healthy elderly who will never develop PD. For instance, although
it is a relatively strong risk factor, the prevalence of SN+ is nearly
ten times higher than the prevalence of PD, meaning, that most
of the individuals with SN+ will not be diagnosed with PD in
their lifetime (Walter, 2011). Therefore, the search for cognitive
patterns in the SN+ group, taken as the sole risk factor, may not
be adequate for addressing pre-diagnostic cognitive impairment
in PD, but may be part of a spectrum of risk factors.
Some limitations of our study need to be mentioned. First, no
correction for multiple testing was applied. Second, the PD group
did not have a TCS examination and therefore the data regarding
the echogenic area in the PD group could not be added to the
correlation analysis. Moreover, knowing that the prevalence of
the SN+ in PD patients is around 90%, approximately eight
patients in PD group could be assumed as having a normal
echogenicity, which could additionally explain the lack of perfect
overlap between the SN+ and PD groups. Third, the relatively
small sample size of the SN+ group (n= 48) may have suppressed
differences especially compared to the SN− group, which could
have been detected at the group level. In summary, this study
revealed that although a cognitive difference between the SN
groups as well as a stepwise impairment toward the cognitive
profile of early PD can be observed in the risk group (SN+) in
some subtests, a perfect continuum in the cognitive deficit pattern
from healthy via PD risk to early PD could not be demonstrated.
In the future, more strictly defined and longitudinally followed
risk/prodromal groups stratified by several markers are needed
in order to differentiate the cognitive profile of individuals with
SN+ that will develop PD, from those of the SN− and non-
PD SN+ group. This will help to establish a likelihood ratio of
prodromal PD in individuals with specific cognitive profiles. The
presence of several other risk and prodromal markers may help
to calculate the risk for prodromal PD according to the new
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research criteria for prodromal PD (Berg et al., 2015). Therefore,
the progression rate of the cognitive impairment prior to the
diagnosis of PD could then be investigated.
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